Hirsutellide A, a New Antimycobacterial Cyclohexadepsipeptide from the Entomopathogenic Fungus *Hirsutella kobayasii*

Namphung Vongvanich,† Prasat Kittakoop,*,‡ Masahiko Isaka,‡ Srisuda Trakulnaleamsai,‡ Saovaluk Vimuttipong,‡ Morakot Tanticharoen,‡ and Yodhathai Thebtaranonth†,‡

Department of Chemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand, and National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Science Park, 113, Paholyothin Road, Klong 1, Klong Luang, Prathumthani, 12120, Thailand

Received February 20, 2002

A new cyclohexadepsipeptide, named hirsutellide A (**1**), was isolated from a cell extract of the entomopathogenic fungus *Hirsutella kobayasii* BCC 1660. The structure of **1** was elucidated by analyses of spectroscopic data, and its absolute stereochemistry was addressed by the use of Marfey's method. Hirsutellide A (**1**) exhibited antimycobacterial and antimalarial activities, but was inactive toward the Vero cell line (at 50 μg/mL).

The incidence of tuberculosis has rapidly increased worldwide, particularly among those associated with HIV infection. It is estimated that approximately one-third of the global population is infected with *Mycobacterium tuberculosis* and that seven to eight million new cases of tuberculosis occur each year.[1] Development of new drugs for use against the emerging drug-resistant strains of *M. tuberculosis* is therefore urgently needed. As part of our continuing search for biologically active compounds from plants and microorganisms,[2] we report herein a new antimycobacterial cyclohexadepsipeptide, named hirsutellide A (**1**), from a cell extract of *Hirsutella kobayasii* BCC 1660. It should be noted that entomopathogenic fungi of the genus *Hirsutella* have rarely been chemically explored; only a toxic polypeptide, hirsutellin A, has been reported to date.[3]



Hirsutellide A (**1**) was obtained as an off-white solid. Its IR exhibited characteristic stretchs of an amide NH (3292 cm^{-1}), an ester carbonyl (1752 cm^{-1}), and amide carbonyls (1663 and 1634 cm^{-1}). The ^{1}H NMR spectrum ($CDCl_3$) showed signals of protons of three methyl groups (singlet at δ_H 3.27, doublet at δ_H 0.87, and triplet at δ_H 0.91), three nonequivalent methylenes at δ_H 1.19−4.46, two downfield methines at δ_H 4.93 and 5.63, aromatic protons at δ_H 7.16−7.28, and an amide NH at δ_H 7.57. Analyses of ^{13}C NMR, DEPT, and HMQC spectral data revealed that hirsutellide A (**1**) possessed 18 carbons (two equivalent carbon signals at δ_C 129.1 (C-5 and C-9) and δ_C 128.6 (C-6 and C-8) of a substituted benzene ring). However, a molecular formula, $C_{36}H_{48}O_8N_4$, was inferred by the ESITOF mass spectrum [accurate mass observed at *m/z* 665.3579 (M + H)$^+$, Δ +2.9 mmu]; hirsutellide A (**1**) therefore possessed a C_2 symmetry. Analyses of ^{1}H−^{1}H COSY, NOESY, HMQC, and HMBC spectral data unambiguously revealed the presence of isoleucine, sarcosine, and 2-hydroxy-3-phenylpropanoic acid in hirsutellide A (**1**) (Figure 1). The ^{1}H−^{1}H COSY spectrum of **1** established the partial structure from H-2′ to H-6′ of the isoleucine residue and also showed correlations between H-2′ of isoleucine to an adjacent amide proton (NH) as well as between H-2 and H-3 of 2-hydroxy-3-phenylpropanoic acid. The HMBC spectrum of hirsutellide A (**1**) assisted in the assignment of the amino acid sequence in **1** (H-2′ of isoleucine to C-1 of 2-hydroxy-3-phenylpropanoic acid and H-2′′ of sarcosine to C-1′ of isoleucine), as depicted in Figure 1. The position of the *N*-methyl at the sarcosine residue was also assigned by HMBC, from which correlations of the singlet methyl protons (δ_H 3.27) to C-1′′ (δ_C 166.8) and C-2′′ (δ_C 51.7) of sarcosine were observed (Figure 1). On the basis of these spectral data, the chemical structure of hirsutellide A (**1**) was secured. Complete assignment of protons and carbons in **1** is shown in Table 1.



Figure 1. Selected HMBC and NOESY correlations of hirsutellide A (**1**).

The relative stereochemistry of hirsutellide A (**1**) was successfully assigned by analyses of the NOESY spectrum. Correlations from the amide proton (NH) to H-3′ of isoleucine and to H-2 of 2-hydroxy-3-phenylpropanoic acid were observed, suggesting that these protons were coplanar (Figure 1). The NOESY spectral data of **1** also revealed correlations between H-2′ and the methyl protons (H-6′) of isoleucine and between H-2′ of isoleucine and the *N*-methyl of sarcosine. The absolute stereochemistry in

* To whom correspondence should be addressed. Tel: +66-2-5646700, ext. 3560. Fax: +66-2-5646707. E-mail: prasat@biotec.or.th.
† Department of Chemistry, Mahidol University.
‡ National Center for Genetic Engineering and Biotechnology.

10.1021/np020055+ CCC: $22.00 © 2002 American Chemical Society and American Society of Pharmacognosy
Published on Web 07/26/2002

Table 1. ^{1}H (400 MHz) and ^{13}C (100 MHz) NMR Spectral Data ($CDCl_3$) of Hirsutellide A (**1**)

unit	δ_C, multiplicity	δ_H, multiplicity (J in Hz)
2-hydroxy-3-phenyl-propanoic acid		
1	168.8, s	
2	74.1, d	5.63, dd (11.8, 2.9)
3	38.7, t	2.74, dd (14.0, 11.9)
		3.68, dd (14.0, 2.8)
4	136.1, s	
5, 9	129.1, d	7.16, br d (7.0)
6, 8	128.6, d	7.28, dd (7.0, 7.0)
7	127.1, d	7.23, m
L-*allo*-isoleucine		
1′	174.1, s	
2′	52.3, d	4.93, dd (10.1, 9.7)
3′	35.8, d	2.24, m
4′	24.2, t	1.19, m
		1.55, m
5′	10.2, q	0.91, t (7.4)
6′	15.4, q	0.87, d (6.7)
NH		7.57, d (9.7)
sarcosine		
1″	166.8, s	
2″	51.7, t	3.20, d (17.1)
		4.46, d (17.2)
*N*Me	37.9, q	3.27, s

hirsutellide A (**1**) was addressed by the use of Marfey's method.[4] Hirsutellide A (**1**) was hydrolyzed and subsequently derivatized with Marfey's reagent (1-fluoro-2,4-dinitrophenyl-5-L-alaninamide, FDAA). HPLC analysis established the L stereochemistry of the isoleucine unit in **1**; however, the reversed-phase column failed to distinguish between L-isoleucine and L-*allo*-isoleucine. The problem was solved using a chiral column, from which the presence of L-*allo*-isoleucine in hirsutellide A (**1**) was firmly established. The absolute configuration at C-2 of 2-hydroxy-3-phenylpropanoic acid was assigned as *R* according to the NOESY spectrum of **1**.

Hirsutellide A (**1**) exhibited antimycobacterial activity with a MIC (minimum inhibitory concentration) of 6−12 μg/mL, but showed no cytotoxic effect toward Vero cells at 50 μg/mL. Additionally, hirsutellide A (**1**) also possessed weak in vitro antimalarial activity, with an IC_{50} value of 2.8 μg/mL.

Experimental Section

General Experimental Procedures. The IR spectra and optical rotations were measured on a Perkin-Elmer 2000 spectrometer and Jasco DIP370 polarimeter, respectively. The UV spectra were recorded on a Cary 1E UV−vis spectrophotometer. The ^{1}H, ^{13}C, DEPT, ^{1}H−^{1}H COSY, NOESY, HMQC, and HMBC experiments were carried out on a Bruker DRX 400 NMR spectrometer, operating at 400 MHz for proton and 100 MHz for carbon. The ESI-TOF mass spectra were obtained from a Micromass LCT mass spectrometer, and the lock mass calibration was applied for the determination of accurate mass.

Fungal Material, Extraction, and Isolation. The fungus *H. kobayasii* BCC 1660 was collected from Kaeng Krachan National Park, Phetchburi, Thailand, and identified by Dr. Nigel Leslie Hywel-Jones of the Mycology Research Unit, National Center for Genetic Engineering and Biotechnology (BIOTEC). The specimen has been deposited (registration no. BCC 1660) at the BIOTEC Culture Collection. *H. kobayasii* BCC 1660 was cultured in potato dextrose broth (5 L culture); cells were separated from the broth by filtration and subsequently extracted twice with CH_2Cl_2 to yield 1.3 g of a crude extract. The extract was subjected to a Sephadex LH-20 column (eluted with MeOH), and the fraction containing hirsutellide A (**1**) was further purified by silica gel column chromatography (eluted with acetone/hexane, gradient elution from 5:95 to 30:70) to afford **1** (18 mg).

Hirsutellide A (1): off-white solid; $[\alpha]^{28}_D$ −13.6° (c 0.25, $CHCl_3$); UV (MeOH) λ_{max} (log ϵ) 212 (4.32) and 257 (sh) nm; IR (KBr) ν_{max} 3292, 3030, 3012, 2967, 2933, 1752, 1663, 1634, 1527, 1464, 1262, 1132, 1095, 1061 cm^{-1}; ^{1}H and ^{13}C NMR, see Table 1; ESITOF MS m/z 665.3579 (M + H)$^+$, calcd for $(C_{36}H_{48}O_8N_4 + H)^+$, 665.3550.

Determination of Amino Acid Configuration by Marfey's Method. A mixture of hirsutellide A (**1**) (1 mg) and 2 M HCl (2 mL) was heated to reflux at 110 °C for 14 h, after which it was evaporated to dryness. The residue was dissolved in 0.5 mL of H_2O, then 2 mL of 1 M $NaHCO_3$ and 1 mL of 1% Marfey's reagent (FDAA)[4] in acetone were added. The reaction mixture was incubated at 37 °C for 1 h, quenched with 0.2 mL of 2 N HCl, and subjected to HPLC analysis (C_{18} reversed-phase column, eluted with MeCN/H_2O (30:70), flow rate 1.0 mL/min, and UV detector set at 340 nm). D and L forms of isoleucine and *allo*-isoleucine were separately derivatized with FDAA in the same manner as that described for **1**. Under the HPLC conditions employed, D- and L-isoleucine (and *allo*-isoleucine) had retention times of 41.26 and 19.62 min, respectively. The residue in **1** was found to be the L form; however, the reversed-phase column failed to distinguish between L-isoleucine and L-*allo*-isoleucine. This problem was solved using a chiral column (ChiraDex, Merck), eluted with MeOH/H_2O (30:70), at a flow rate of 0.7 mL/min. Under these HPLC conditions, L-isoleucine and L-*allo*-isoleucine exhibited retention times of 7.08 and 7.88 min, respectively. The sample was co-injected with standard compounds to finally establish the amino acid from hirsutellide A (**1**) as L-*allo*-isoleucine.

Bioassays. The antimycobacterial activity was assessed against *Mycobacterium tuberculosis* H37Ra using the Microplate Alamar Blue Assay (MABA).[5] Standard drugs, isoniazid and kanamycin sulfate, the reference compounds for the antimycobacterial assay, showed minimum inhibitory concentrations (MICs) of 0.040−0.090 and 2.0−5.0 μg/mL, respectively. The antimalarial activity was evaluated against the parasite *Plasmodium falciparum* (K1, multidrug-resistant strain), which was cultured continuously according to the method of Trager and Jensen.[6] Quantitative assessment of antimalarial activity in vitro was determined by means of the microculture radioisotope technique based upon the method described by Desjardins et al.[7] The inhibitory concentration (IC_{50}) represents the concentration that causes 50% reduction in parasite growth as indicated by the in vitro uptake of [^{3}H]-hypoxanthine by *P. falciparum*. An IC_{50} value of 1 ng/mL was observed for the standard compound, artemisinin, in the same test system. Cytotoxicity was determined by employing the colorimetric method described by Skehan and co-workers.[8] The reference compound, ellipticine, exhibited activity toward the BC-1 and KB cell lines, both with an IC_{50} of 0.3 μg/mL.

Acknowledgment. N.V. is a Ph.D. student under the Royal Golden Jubilee program. We are indebted to the Biodiversity Research and Training Program (BRT) for financial support. The support of the Thailand-Tropical Diseases Research Program (T-2)′ to the antimycobacterial assay laboratory is gratefully acknowledged. Y.T. thanks the National Center for Genetic Engineering and Biotechnology for the Senior Research Fellowship Award.

Supporting Information Available: ^{1}H, ^{13}C, ^{1}H−^{1}H COSY, NOESY, HMQC, HMBC, and ESI-TOF MS spectra of hirsutellide A (**1**). This material is available free of charge via the Internet at http://pubs.acs.org.

References and Notes

(1) (a) Small, P. M.; Schecter, G. F.; Goodman, P. C.; Sande, M. A.; Chaisson, R. E.; Hopewell, P. C. *N. Engl. J. Med.* **1991**, *324*, 289−294. (b) Bradford, W. Z.; Martin, J. N.; Reingold, A. L.; Schecter, G. F.; Hopewell, P. C.; Small, P. M. *Lancet* **1996**, *348*, 928−931.

(2) (a) Vongvanich, N.; Kittakoop, P.; Kramyu, J.; Tanticharoen, M.; Thebtaranonth, Y. *J. Org. Chem.* **2000**, *65*, 5420−5423. (b) Kittakoop, P.; Wanasith, S.; Watts, P.; Kramyu, J.; Tanticharoen, M.; Thebtaranonth, Y. *J. Nat. Prod.* **2001**, *64*, 385−388. (c) Boonphong, S.;

Kittakoop, P.; Isaka, M.; Palittapongarnpim, P.; Jaturapat, A.; Danwisetkanjana, K.; Tanticharoen, M.; Thebtaranonth, Y. *Planta Med.* **2001**, *67*, 279−281. (d) Chinworrungsee, M.; Kittakoop, P.; Isaka, M.; Rungrod, A.; Tanticharoen, M.; Thebtaranonth, Y. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1965−1969. (e) Boonphong, S.; Kittakoop, P.; Isaka, M.; Pittayakhajonwut, D.; Tanticharoen, M.; Thebtaranonth, Y. *J. Nat. Prod.* **2001**, *64*, 965−967.
(3) Mazet, I.; Vey, A. *Microbiology* **1995**, *141*, 1343−1348.
(4) Fujii, K.; Shimoya, T.; Ikai, Y.; Oka, H.; Harada, K. *Tetrahedron Lett.* **1998**, *39*, 2579−2582.
(5) Collins, L.; Franzblau, S. G. *Antimicrob. Agents Chemother.* **1997**, *41*, 1004−1009.
(6) Trager, W.; Jensen, J. B. *Science* **1976**, *193*, 673−675.
(7) Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. *Antimicrob. Agents Chemother.* **1979**, *16*, 710−718.
(8) Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. *J. Natl. Cancer Inst.* **1990**, *82*, 1107−1112.

NP020055+